The overall goal of the Biology of Breast Cancer (BBC) Program is to bring together multidisciplinary expertise for collaborative discovery of molecular alterations and signatures of breast cancer and to translate these findings into new strategies for effective detection, diagnosis, and treatment Central thematic aims are 1) Exploit hormonal pathways in preclinical models for molecular target identification and new strategies for therapy and prevention;2) Improve diagnostic tumor classification and establish new prognostic and predictive molecular signatures to facilitate tailored treatment;3} Develop innovative strategies and technologies for early detection of cancer and for monitoring of therapy response and disease recurrence. The BBC Program is the renamed continuation of the Endocrine Mechanisms and Hormone Action in Cancer (EMHAC) Program, funded since 2007. During the first four years the EMHAC program grew by successful external recruitment and internal mentored development of junior faculty, with total peer-reviewed funding rising from $4.2 million to $9.3 million in 2011. This growth ofthe EMHAC Program, with a number of productive and leading investigators studying breast cancer or prostate cancer, allowed KCC to strategically split off a subgroup of investigators to form the new Biology of Prostate Cancer (BPC) Program in 2011. Current BBC Program members have authored more than 400 publications between 2007 and 2012, including publications in high impact journals such as Cell, Science, JCO, JNCI, Mol Cell, JCI, MCB, and PNAS. Collaborative interactions by BBC members have been high during the past funding period as documented by 45% intra-programmatic and 28% inter-programmatic publications. The BBC program includes seventeen members from 10 departments and three schools at TJU and Drexel. Dr. Hallgeir Rui (Cancer Biology) has served as Program Leader since 2006, and Dr. Russell Schilder (Medical Oncology) was recruited as Co-Leader in 2011. A series of collaborative and interdisciplinary program initiatives have been supported by extensive cancer center pilot funding. Current annual peer-reviewed program funding of BBC members totals $5.9 million with NCI funding of $ 3.8 million. Multi-investigator grants, including a 5-year Komen Promise program grant for therapy-relevant stratification of breast cancer patients, extensive program meetings, and a high proportion of programmatic collaborative publications attest to successful program activities and interactions.

Public Health Relevance

Each year 1.3 million new cases of breast cancer are diagnosed worldwide and nearly half a million women die from breast cancer. The members of the BBC Program jointly provide critical strength in laboratory and patient-oriented research on breast cancer, with emerging expertise in related malignancies of other hormone responsive female reproductive organs such as uterus and ovaries. Collaborative efforts will translate cancer biology, molecular profiling, and patient characteristics into more effective and individualized care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA056036-14
Application #
8517959
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-07-15
Project End
2018-05-31
Budget Start
2013-06-18
Budget End
2014-05-31
Support Year
14
Fiscal Year
2013
Total Cost
$212,792
Indirect Cost
$75,392
Name
Thomas Jefferson University
Department
Type
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Ozaki, Shinji; Vuyyuru, Raja; Kageyama, Ken et al. (2016) Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization. Am J Pathol 186:43-56
Teh, Jessica L F; Purwin, Timothy J; Greenawalt, Evan J et al. (2016) An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma. Cancer Res 76:5455-66
Lu, Huimin; Wang, Tao; Li, Jing et al. (2016) αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor. Cancer Res 76:5163-74
Zhao, Yongtong; Shapiro, Sandor S; Eto, Masumi (2016) F-actin clustering and cell dysmotility induced by the pathological W148R missense mutation of filamin B at the actin-binding domain. Am J Physiol Cell Physiol 310:C89-98
Singh, Amrita; Fedele, Carmine; Lu, Huimin et al. (2016) Exosome-mediated Transfer of αvβ3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype. Mol Cancer Res 14:1136-1146
Hutcheson, Jack; Balaji, Uthra; Porembka, Matthew R et al. (2016) Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease. Clin Cancer Res 22:3606-17
Pattison, Amanda M; Blomain, Erik S; Merlino, Dante J et al. (2016) Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins. Infect Immun 84:3083-91
Zhao, Qian; Deng, Shengqiong; Wang, Guangxue et al. (2016) A direct quantification method for measuring plasma MicroRNAs identified potential biomarkers for detecting metastatic breast cancer. Oncotarget 7:21865-74
Dowling, John P; Cai, Yubo; Bertin, John et al. (2016) Kinase-independent function of RIP1, critical for mature T-cell survival and proliferation. Cell Death Dis 7:e2379
Curry, Joseph M; Tassone, Patrick; Cotzia, Paolo et al. (2016) Multicompartment metabolism in papillary thyroid cancer. Laryngoscope 126:2410-8

Showing the most recent 10 out of 674 publications